ABSTRACT The concentrations of three known elastase inhibitors (a, proteinase inhibitor, antileucoprotease, and a2 macroglobulin) have been determined in the sputum of six patients with obstructive bronchitis over five consecutive days. Antileucoprotease was the major inhibitor measured and potentially could provide more than 80% of the elastase inhibition, whereas the contribution of a2 macroglobulin was less than 0.2%. Comparison with the inhibitory capacity of the secretions active against human neutrophil elastase showed that the inhibitors could account for only about half of the inhibition measured. This suggests the presence of a substantial amount of unrecognised inhibitor. Corticosteroid treatment in 10 patients reduced the mean a, proteinase inhibitor concentration (p < 0.025) from 18.6 pg/ml (SD 22.5) to 9.8 (6.6). Antileucoprotease, however, increased (p < 0.05) from 20.5 jg/ml (24.3) to 39.3 (23.4). These changes were associated with an increase in elastase inhibition (p < 0.025) from 180 (160) yg elastase/ml secretion to 310 (130), suggesting a beneficial effect of steroid treatment on the antielastases in lung secretions.
Although the cause of emphysema remains uncertain, the currently favoured hypothesis is that proteolytic enzymes with elastolytic properties digest lung elastin, leading to structural changes and hence dilatation of air spaces.' Before the enzymes can attack lung elastin, however, they must overcome the local inhibitors. The enzyme that has been implicated in human emphysema is neutrophil elastase.' Hence the balance between this enzyme and elastase inhibitors may play a crucial part in the development of emphysema.
There has been controversy about the nature of antielastases in lung secretion. Gadek etal2 initially presented data suggesting that the only antielastase of the alveolar structure was a, antitrypsin (also called a, proteinase inhibitor). Although several low molecular weight inhibitors of elastase have been identified in lung secretions,' it was thought that these were inhibitors protecting bronchial rather than alveolar structures. 3 Recent immunohistochemical evidence, however, has shown that these inhibitors are present in periph-Accepted 6 December 1985 eral airways. 4 Furthermore, they can be recovered by bronchoalveolar lavage' and contribute substantially to the elastase inhibition in lavage samples.56 In addition, we have shown that the relative concentrations of the low molecular weight inhibitors and a, proteinase inhibitor, as well as their function, are broadly similar in bronchial secretions (sputum) and bronchoalveolar lavage fluid. 5 The purpose of the present study was to assess the known antielastases in sputum sol phase from patients with chronic bronchitis and emphysema. In particular, we were interested in their contribution to the antielastase activity of the secretion and whether or not this varied from day to day in a group of subjects. Furthermore Antileucoprotease was the major inhibitor in terms of moles/100 moles of total measured inhibitor. This inhibitor accounted for more than 60% of the measured inhibitors in all secretions. Alpha1 proteinase inhibitor was the second major inhibitor, representing about 10-20% of the inhibitors measured. The contribution of a2 macroglobulin was usually less than (table 1); the between subject variability (cofficient of variance for the five days was 32%, 35.3%, 24.3%, 44.8%, and 53.6%. Figure 2 summarises the relative contributions of antileucoprotease and a, proteinase inhibitor to total inhibition and to the proportion unaccounted for. The potential contribution of 22 macroglobulin was too small to be illustrated graphically.
EFFECT OF STEROIDS
Because of the large between subject variability, 10 subjects were included in the study of the effect of steroid treatment. Measurements of CX2 macroglobulin were not made because of its minimal contribution to elastase inhibition. The results are summarised in 
Discussion
The results of this study show that wide interindividual variability exists for both the quantity and The measurement of lung inhibitors, particularly a, proteinase inhibitor, may present problems when the protein in the secretion is physicochemically different from the protein standards. 5 The assay for a2 macroglobulin is clearly reproducible and because of its low concentration even major inaccuracies in its measurement would be unlikely to effect the overall results. The oa, proteinase inhibitor assay is also reproducible, but a, proteinase inhibitor can be overestimated in immune assays if a major proportion has undergone proteolytic cleavage.9 Proteolytic cleavage, however, also inactivates oal proteinase inhibitor as an inhibitor. Thus if such a change had occurred it would lead to overestimation of its possible contribution to elastase inhibition as studied here.
The assay for antileucoprotease is the least precise, although even the 13% between batch coefficient of variation would not be sufficient to produce a major underestimation of its concentration. Such a change would have to occur regularly to explain the discrepancy between measured inhibitors and the inhibitory capacity. Inaccuracies in the estimation of inhibitor are therefore unlikely to account for the results, which 445 have led to the suggestion that unknown inhibitors exist.
Several errors may arise in assessing enzyme inhibition with low molecular weight substrate such as that used here. 5 In particular, it is vital that the activity of the enzyme is determined by active site titration as a degree of inactivation occurs with purification.
Failure to take this into account will result in an overestimation of enzyme inhibition. This is not the case in the studies reported here since it is our routine practice to report results in terms of active enzyme only.
Alpha2 macroglobulin does not inactivate neutrophil elastase when small peptide substrates are used.'8 This could lead to an apparent discrepancy between the expected and observed inhibition of neutrophil elastase when the current methods are used. The contribution of a2 macroglobulin is potentially very small, however, and would if anything lead to an overestimation of its contribution to the neutrophil elastase inhibition seen here.
On balance the results seem to indicate that elastase inhibitors other than those measured are present in considerable quantities in these samples. As a further confirmation, we prepared mixtures of active antileucoprotease, a, proteinase inhibitor, and a2 macroglobulin in ratios similar to those in our bronchitic sputum. The inhibition of neutrophil elastase determined by the same assay is shown in figure 1 and confirms that the regression line passes close to molar equivalence (see under "Results").
The nature of the unidentified inhibitor or inhibitors is uncertain. Several low molecular weight inhibitors of elastase have been purified by different research groups.' The relationship between these inhibitors is not clear and may partly represent methodological problems of purification. Indeed, Keuppers and Bromke'9 were able to purify several different molecular weight inhibitors with immunological similarity from the same samples. It is thus possible that all of the inhibitors isolated by different groups may be fragments of the same protein. If this is the case, the purification that takes place before an antiserum is developed may result in immunological assays that do not quantify all forms of the parent protein equally. The net result could be an underestimation of antileucoprotease or its precursors and hence an underestimation of its contribution to the observed enzyme inhibition, and this could explain our results. Clearly further studies are required to clarify these possibilities. Indeed, whether or not antileucoprotease, as measured here, and the bronchial mucus proteinase inhibitor measured in a previous collaborative study5 are the 
